1. Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
- Author
-
Francesca Conradie, G Wills, M. Olugbosi, A Calatroni, Mendel Carl M, Pauline Howell, Daniel Everitt, E Sun, N Ngubane, Aliasgar Esmail, A. del Parigi, Angela M. Crook, Melvin Spigelman, Andreas H. Diacon, Olatunde Olayanju, Keertan Dheda, and Suzette Oelofse
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Drug ,medicine.medical_specialty ,Extensively Drug-Resistant Tuberculosis ,media_common.quotation_subject ,030106 microbiology ,Antitubercular Agents ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Tuberculosis, Multidrug-Resistant ,Culture conversion ,medicine ,Humans ,Prospective Studies ,Diarylquinolines ,media_common ,business.industry ,Linezolid ,Regimen ,Infectious Diseases ,030228 respiratory system ,chemistry ,Nitroimidazoles ,Pretomanid ,Relative risk ,Cohort ,Bedaquiline ,business - Abstract
BACKGROUND: There are no data comparing the 6–9 month oral three-drug Nix regimen (bedaquiline, pretomanid and linezolid [BPaL]) to conventional regimens containing bedaquiline (B, BDQ) and linezolid (L, LZD).METHODS: Six-month post end-of-treatment outcomes were compared between Nix-TB (n = 109) and 102 prospectively recruited extensively drug-resistant TB patients who received an ˜18-month BDQ-based regimen (median of 8 drugs). A subset of patients received BDQ and LZD (n = 86), and a subgroup of these (n = 75) served as individually matched controls in a pairwise comparison to determine differences in regimen efficacy.RESULTS: Favourable outcomes (%) were significantly better with BPaL than with the B–L-based combination regimen (98/109, 89.9% vs. 56/86, 65.1%; adjusted relative risk ratio [aRRR] 1.35; P < 0.001) and in the matched pairwise analysis (67/75, 89.3% vs. 48/75, 64.0%; aRRR 1.39; P = 0.001), despite significantly higher baseline bacterial load and prior second-line drug exposure in the BPaL cohort. Time to culture conversion (P < 0.001), time to unfavourable outcome (P < 0.01) and time to death (P < 0.03) were significantly better or lower with BPaL than the B-L-based combinations.CONCLUSION: The BPaL regimen (and hence substitution of multiple other drugs by pretomanid and/or higher starting-dose LZD) may improve outcomes in drug-resistant TB patients with poor prognostic features. However, prospective controlled studies are required to definitively answer this question.
- Published
- 2021
- Full Text
- View/download PDF